Considering the critical roles of UCP-2 in cancer progression and the potential correlation between HER2 signaling and UCP-2 expression, we proposed that suppression of UCP-2 might be a feasible way to increase initiate response rate and/or enhance efficacy in trastuzumab in breast cancer therapy. This evidence concerns the gene ERBB2 and breast cancer.